Clinical trial · Interventional
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
Pilot for a Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer Versus Anastrozole and Subsequent Ant-Oestrogen Therapy Delayed Until After Radiotherapy
NCT00126360CI-TRIAL-00000203unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomized study comparing the use of Anastrozole before and continuing during radiotherapy for breast cancer compared to the use of anastrozole after irradiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Timing of Anastrozole in respect to radiotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Local failure within irradiation volume
Secondary outcomes (3)
- measure
- Early quality of life
- measure
- Lung fibrosis
- measure
- Also demonstration of recruitment capacity at lead trial centres
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 or more years. No upper limit. * Post total mastectomy or lumpectomy. All planned surgery complete. * Margins clear (no tumour contacting the inked margin) * Tumour oestrogen or progesterone receptor positive * Planned dose to irradiated volumes at least the biological equivalent of 45 Gy in 25 fractions or more. * ECOG 0-2 * Patients post menopausal using same criteria as ATAC study. * Written informed consent Exclusion Criteria: * Previous radiotherapy to the area to be treated. * Previous invasive malignancy within 5 years of current breast cancer diagnosis with the exception of cervix in-situ or skin cancer other than melanoma. * Patients with clinical evidence of metastatic disease. * Previous hormonal breast therapy. * Ongoing hormone replacement therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.